NASDAQ NMS - GLOBAL MARKET · BIIB

-1.35% · -$3.00 · Vol 517.5K

Market closed · last close 4:00 PM ET · price as of 16:54:50 ET

Biogen Inc

Biotechnology

$218.50

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET · BIIB

Methodology

BIIB

Biogen Inc

Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET

66/100

BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

66/ 100

Veridion Score

BUY BIAS · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is BIIB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move BIIB next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Jun 9
CongressChecking access
Gilbert Ray Cisneros, Jr. sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 5
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 2
CongressChecking access
Maria Elvira Salazar sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 27
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 15
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 12
CongressChecking access
Maria Elvira Salazar purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 11
CongressChecking access
Maria Elvira Salazar purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 13
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Biogen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1991

Employees

Country

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$221.17

Day high

$222.00

Day low

$216.78

Previous close

$221.50

52W high

$222.00

-1.58% from high

52W low

$135.67

96% of range

Market cap

$32.3B

P/E

21.19×

EPS

$10.31

Beta

-0.21

Shares out

147.8M

Volume

517.5K

0.59× rel vol

Avg volume

872.5K

VWAP

$218.20

Price history computed in-house

+0.79%

+7.66%

+13.67%

+65.25%

YTD

+24.15%

SMA 50 $207.41 · above

SMA 200 $189.63 · above

52W position 96%

BIIB overview

Veridion Score

Registered · 2026-08-28

6 of 6 factors measured

Latest receipt rows

Gilbert Ray Cisneros, Jr. · Sale

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around BIIB.Congress disclosuresOpen receipt and filing context for BIIB.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

BIIB insider activity

Biogen Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not evaluated: the SEC filing index could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for BIIB.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in BIIB

Congress tracker Open ticker disclosure ledger →

Gilbert Ray Cisneros, Jr.Sell

Ticker SAN SM Biogen Inc. - Common Stock · Transaction Jun 9, 2026 · Filed Jul 2, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Buy

BIIB · Transaction Jun 5, 2026 · Filed Jul 2, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Buy

Biogen Inc. - Common Stock · Transaction Jun 5, 2026 · Filed Jul 2, 2026 · $1,001 to $15,000

Official filing ↗

Maria Elvira SalazarSell

BIIB · Transaction Jun 2, 2026 · Filed Jul 7, 2026 · $15,001 to $50,000

Official filing ↗

Ro KhannaSell

BIIB Common Stock · Transaction May 27, 2026 · Filed Jun 9, 2026 · $1,001 to $15,000

Official filing ↗

Federal contracts

BIIB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for BIIB in this window.

Lobbying spend

BIIB lobbying filings, year to date.

Registered lobbying filings matched to Biogen Inc.

$3.4M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)Medicare/Medicaid Health Issues Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues

Filing

$1.5M

BIOGEN

Apr 20, 2026

Filing

$1.1M

BIOGEN

Jul 20, 2026

Filing

$770.0K

BIOGEN

Jan 19, 2026